

Electronic supplementary material

ESM 2. Summary and specific types of chemotherapy

chemotherapy summary	specific chemotherapy substances
Alkylating agents	Cisplatin, Carboplatin, Oxaliplatin, Temozolomid, Cyclophosphamide, Melphalan, Bleomycin, Chlorambucil, Estramustin, Mitomycin, Trabectedine
Antimetabolites	Pemetrexed, 6-Mercaptopurin, Cytarabine, Gemcitabine, Capecitabine
Mitotic inhibitors/Plant alkaloids	Vincristine, Vinorelbine, Docetaxel, Paclitaxel, Cabazitaxel
Antiandrogens	Bicalutamide, Leuprorelinacetat, Abiraterone
GnRH-Agonist	Goserelin
Corticosteroids	Prednisolone, Dexamethasone
Monoclonal antibodies	Rituximab, Obinutuzumab, PSMA-Lutetium-Ligand, Brentuximab, Daratumumab, Trastuzumab, Catumaxomab, Tafasitamab, Pertuzumab
Topoisomerase inhibitors	Irinotecan, Etoposid, Topotecan
Anthracyclines	Daunorubicin, Doxorubicin, Caelyx Epirubicin
Kinase/proteasome inhibitors	Imatinib, Masitinib, Cabozantinib, Palbociclib, Sorafenib, Erlotinib, Sunitinib, Nintedanib, Cetuximab, Tarceva, Bortezomib
VEGF inhibitors	Bevacizumab, Ramucirumab, Aflibercept
Immune checkpoint therapy	Nivolumab, Ipilimumab, Pembrolizumab, Atezolizumab
PSMA ligands	PSMA-Lutetium-177-Ligand, PSMA-Actinium-225-Ligand
Immune modulating agents (IMiDs)	Lenalidomid, Interferon
Antifolates	Methotrexate
Aromatase inhibitors	Letrozol, Exemestan
Others	Biphosphonates, Faslodex, Lipidol, Embocept, Mistletoe therapy, Asperginase, Denosumab